Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Operating Margin (2016 - 2025)

Historic Operating Margin for UroGen Pharma (URGN) over the last 9 years, with Q3 2025 value amounting to 99.65%.

  • UroGen Pharma's Operating Margin fell 300400.0% to 99.65% in Q3 2025 from the same period last year, while for Sep 2025 it was 138.22%, marking a year-over-year decrease of 445200.0%. This contributed to the annual value of 107.06% for FY2024, which is 278300.0% down from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Operating Margin is 99.65%, which was down 300400.0% from 171.17% recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Operating Margin registered a high of 62.09% during Q4 2023, and its lowest value of 348.88% during Q1 2021.
  • For the 5-year period, UroGen Pharma's Operating Margin averaged around 135.32%, with its median value being 118.27% (2024).
  • In the last 5 years, UroGen Pharma's Operating Margin skyrocketed by 83732600bps in 2021 and then plummeted by -529000bps in 2025.
  • UroGen Pharma's Operating Margin (Quarter) stood at 123.13% in 2021, then grew by 9bps to 112.1% in 2022, then surged by 45bps to 62.09% in 2023, then crashed by -81bps to 112.59% in 2024, then grew by 11bps to 99.65% in 2025.
  • Its last three reported values are 99.65% in Q3 2025, 171.17% for Q2 2025, and 182.26% during Q1 2025.